A195940 Stock Overview
HK inno.N Corporation engages in the pharmaceutical business in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HK inno.N Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩38,200.00 |
| 52 Week High | ₩47,450.00 |
| 52 Week Low | ₩27,900.00 |
| Beta | 0 |
| 1 Month Change | 0.26% |
| 3 Month Change | -11.78% |
| 1 Year Change | 17.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| A195940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.7% | 5.5% | 3.4% |
| 1Y | 17.0% | 8.1% | 7.1% |
Price Volatility
| A195940 volatility | |
|---|---|
| A195940 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,695 | Dal-Won Kwak | www.inno-n.com |
HK inno N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition.
HK inno.N Corporation Fundamentals Summary
| A195940 fundamental statistics | |
|---|---|
| Market cap | ₩1.08t |
| Earnings (TTM) | ₩41.49b |
| Revenue (TTM) | ₩839.63b |
0.0x
P/E Ratio0.0x
P/S RatioIs A195940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A195940 income statement (TTM) | |
|---|---|
| Revenue | ₩839.63b |
| Cost of Revenue | ₩491.45b |
| Gross Profit | ₩348.18b |
| Other Expenses | ₩306.69b |
| Earnings | ₩41.49b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A195940 perform over the long term?
See historical performance and comparison